These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B. Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides. Wang Y; Diep JK; Yu RZ; Hurh E; Karwatowska-Prokopczuk E; Schneider E; Henry S; Bhanot S; Geary RS J Clin Pharmacol; 2023 Jan; 63(1):21-28. PubMed ID: 35801818 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955 [TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960 [TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Shadid M; Badawi M; Abulrob A Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122 [TBL] [Abstract][Full Text] [Related]
7. In Vivo Metabolite Profiles of an Li XQ; Elebring M; Dahlén A; Weidolf L Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729 [TBL] [Abstract][Full Text] [Related]
8. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys. Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease. Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341 [TBL] [Abstract][Full Text] [Related]
10. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice. Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372 [TBL] [Abstract][Full Text] [Related]
12. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides. Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483 [TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610 [TBL] [Abstract][Full Text] [Related]
14. Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction. Shin M; Meda Krishnamurthy P; Devi G; Watts JK Nucleic Acid Ther; 2022 Feb; 32(1):66-73. PubMed ID: 34928745 [TBL] [Abstract][Full Text] [Related]
15. Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics. Cai Y; Lou C; Wengel J; Howard KA Methods Mol Biol; 2020; 2176():163-174. PubMed ID: 32865790 [TBL] [Abstract][Full Text] [Related]
16. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225 [TBL] [Abstract][Full Text] [Related]
17. Integrated Assessment of the Clinical Performance of GalNAc Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431 [TBL] [Abstract][Full Text] [Related]
18. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935 [TBL] [Abstract][Full Text] [Related]
19. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding. Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959 [TBL] [Abstract][Full Text] [Related]